Alnylam Pharmaceuticals
ALNY
#686
Rank
C$51.37 B
Marketcap
C$384.82
Share price
1.59%
Change (1 day)
-13.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): C$1.20 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$4.28 Billion. In 2025 the company made an earning of C$0.89 Billion, an increase over its 2024 earnings that were of -C$0.34 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) C$1.20 B34.52%
2025 C$0.89 B-369.48%
2024 -C$0.34 Billion-24.59%
2023 -C$0.45 Billion-67.84%
2022 -C$1.37 Billion36.93%
2021 -C$1 Billion-8.04%
2020 -C$1.09 Billion-15.66%
2019 -C$1.29 Billion12.23%
2018 -C$1.15 Billion62.91%
2017 -C$0.71 Billion17.78%
2016 -C$0.6 Billion43.44%
2015 -C$0.42 Billion60.69%
2014 -C$0.26 Billion98.2%
2013 -C$0.14 Billion
2011 -C$77.28 Million27.48%
2010 -C$60.62 Million-10.92%
2009 -C$68.05 Million95.77%
2008 -C$34.76 Million
2006 -C$55.68 Million-9.13%
2005 -C$61.28 Million34.74%
2004 -C$45.48 Million36.79%
2003 -C$33.25 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
C$22.24 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$10.79 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$7.26 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C$34.48 M-97.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-C$66.86 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-C$0.33 Billion-126.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$3.20 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-C$0.23 Billion-118.38%๐Ÿ‡บ๐Ÿ‡ธ USA